Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 1, 2013, Pages 40-48

  Todoroff, Julie ^a   Ucakar, Bernard ^a   Inglese, Malory ^a   Vandermarliere, Sophie ^a   Fillee, Catherine ^b   Renauld, Jean Christophe ^a   Huygen, Kris ^c   Vanbever, Rita ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Antigen 85A; CpG oligonuleotide; Poloxamer 407; Pulmonary vaccination; Tuberculosis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; INTERLEUKIN 5; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS ANTIGEN 85A; POLOXAMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHENOTYPE; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNITY, CELLULAR; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; OLIGODEOXYRIBONUCLEOTIDES; POLOXAMER;

EID: 84876941000     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.020     Document Type: Article

References (33)

1. World Health Organization, Tuberculosis. Fact sheet n°104, 2010.
2. A.C. Hesseling, J. Caldwell, M.F. Cotton, B.S. Eley, H.B. Jaspan, K. Jennings, B.J. Marais, J. Nuttall, H. Rabie, P. Roux, and H.S. Schaaf BCG vaccination in South African HIV-exposed infants-risks and benefits S. Afr. Med. J. 99 2009 88 91
3. P. Andersen, and T.M. Doherty The success and failure of BCG-implications for a novel tuberculosis vaccine Nat. Rev. Microbiol. 3 2005 656 662
4. R. Rowland, and H. McShane Tuberculosis vaccines in clinical trials Expert Rev. Vaccines 10 2011 645 658
5. D. Lu, and A.J. Hickey Pulmonary vaccine delivery Expert Rev. Vaccines 6 2007 213 226
6. V.J. Sullivan, J.A. Mikszta, P. Laurent, J. Huang, and B. Ford Noninvasive delivery technologies: respiratory delivery of vaccines Expert Opin. Drug Deliv. 3 2006 87 95
7. D.F. Hoft Tuberculosis vaccine development: goals, immunological design, and evaluation Lancet 372 2008 164 175
8. M. Friede, and M.T. Aguado Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems Adv. Drug Deliv. Rev. 57 2005 325 331
9. P. Alexandridis, and T. Alan Hatton Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling Colloids Surf. A 96 1995 1 46
10. G. Dumortier, J.L. Grossiord, F. Agnely, and J.C. Chaumeil A review of poloxamer 407 pharmaceutical and pharmacological characteristics Pharm. Res. 23 2006 2709 2728
11. K. Huygen, J. Content, O. Denis, D.L. Montgomery, A.M. Yawman, R.R. Deck, C.M. DeWitt, I.M. Orme, S. Baldwin, C. D'Souza, A. Drowart, E. Lozes, P. Vandenbussche, J.P. Van Vooren, M.A. Liu, and J.B. Ulmer Immunogenicity and protective efficacy of a tuberculosis DNA vaccine Nat. Med. 2 1996 893 898
12. H. McShane, A.A. Pathan, C.R. Sander, S.M. Keating, S.C. Gilbert, K. Huygen, H.A. Fletcher, and A.V. Hill Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans Nat. Med. 10 2004 1240 1244
13. T. Gartner, M. Baeten, S. Otieno, H. Revets, B.P. De, and K. Huygen Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A Immunol. Lett. 111 2007 26 35
14. S. D'Souza, V. Rosseels, M. Romano, A. Tanghe, O. Denis, F. Jurion, N. Castiglione, A. Vanonckelen, K. Palfliet, and K. Huygen Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis Infect. Immun. 71 2003 483 493
15. A. Minne, J. Louahed, S. Mehauden, B. Baras, J.C. Renauld, and R. Vanbever The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response Immunology 122 2007 316 325
16. E. Torrado, and A.M. Cooper IL-17 and Th17 cells in tuberculosis Cytokine Growth Factor Rev. 21 2010 455 462
17. E.K. Forbes, C. Sander, E.O. Ronan, H. McShane, A.V. Hill, P.C. Beverley, and E.Z. Tchilian Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice J. Immunol. 181 2008 4955 4964
18. T.J. Scriba, M. Tameris, N. Mansoor, E. Smit, L. van der Merwe, K. Mauff, E.J. Hughes, S. Moyo, N. Brittain, A. Lawrie, H. Mulenga, K.M. de, S. Gelderbloem, A. Veldsman, M. Hatherill, H. Geldenhuys, A.V. Hill, G.D. Hussey, H. Mahomed, W.A. Hanekom, and H. McShane Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants J. Infect. Dis. 203 2011 1832 1843
19. M. Ballester, C. Nembrini, N. Dhar, T.A. de, P.C. de, M. Pasquier, E. Simeoni, A.J. van der Vlies, J.D. McKinney, J.A. Hubbell, and M.A. Swartz Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis Vaccine 29 2011 6959 6966
20. S. Shi, and A.J. Hickey PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B Pharm. Res. 27 2010 350 360
21. M.L. Kang, H.L. Jiang, S.G. Kang, D.D. Guo, D.Y. Lee, C.S. Cho, and H.S. Yoo Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin Vaccine 25 2007 4602 4610
22. M.A. Westerink, S.L. Smithson, N. Srivastava, J. Blonder, C. Coeshott, and G.J. Rosenthal ProJuvant (pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid Vaccine 20 2001 711 723
23. C.M. Coeshott, S.L. Smithson, E. Verderber, A. Samaniego, J.M. Blonder, G.J. Rosenthal, and M.A. Westerink Pluronic F127-based systemic vaccine delivery systems Vaccine 22 2004 2396 2405
24. F. Roohvand, M.R. Aghasadeghi, S.M. Sadat, A. Budkowska, and A.R. Khabiri HCV core protein immunization with montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses Biochem. Biophys. Res. Commun. 354 2007 641 649
25. N. Spitzer, A. Jardim, D. Lippert, and R.W. Olafson Long-term protection of mice against Leishmania major with a synthetic peptide vaccine Vaccine 17 1999 1298 1300
26. E.O. Ronan, L.N. Lee, E.Z. Tchilian, and P.C. Beverley Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine Vaccine 28 2010 5179 5184
27. D.M. Klinman, D. Currie, I. Gursel, and D. Verthelyi Use of CpG oligodeoxynucleotides as immune adjuvants Immunol. Rev. 199 2004 201 216
28. J.D. Marshall, K.L. Fearon, D. Higgins, E.M. Hessel, H. Kanzler, C. Abbate, P. Yee, J. Gregorio, T.D. Cruz, J.O. Lizcano, A. Zolotorev, H.M. McClure, K.M. Brasky, K.K. Murthy, R.L. Coffman, and G.V. Nest Superior activity of the type C class of ISS in vitro and in vivo across multiple species DNA Cell Biol. 24 2005 63 72
29. M.J. Newman, C.W. Todd, and M. Balusubramanian Design and development of adjuvant-active non-ionic block copolymers J. Pharm. Sci. 87 1998 1357 1362
30. E.V. Batrakova, S. Li, V.Y. Alakhov, D.W. Miller, and A.V. Kabanov Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells J. Pharmacol. Exp. Ther. 304 2003 845 854
31. J. Todoroff, and R. Vanbever Fate of nanomedicines in the lungs Curr. Opin. Colloid Interface Sci. 16 2011 246 254
32. S.D. Singh-Joy, and V.C. McLain Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics Int. J. Toxicol. 27 Suppl 2 2008 93 128
33. H. Choi, M. Lee, M. Kim, and C. Kim Effect of additives on the physicochemical properties of liquid suppository bases Int. J. Pharm. 190 1999 13 19